Sphera Funds Management LTD. purchased a new stake in Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 620,000 shares of the company's stock, valued at approximately $3,652,000. Sphera Funds Management LTD. owned approximately 3.87% of Alpha Cognition as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Boothbay Fund Management LLC bought a new stake in shares of Alpha Cognition in the 4th quarter valued at about $1,284,000. Bleichroeder LP acquired a new stake in Alpha Cognition in the 4th quarter worth approximately $1,024,000. Rosalind Advisors Inc. acquired a new stake in Alpha Cognition in the 4th quarter worth approximately $1,489,000. Aristides Capital LLC acquired a new stake in Alpha Cognition in the 4th quarter worth approximately $1,178,000. Finally, Altium Capital Management LLC acquired a new stake in Alpha Cognition in the 4th quarter worth approximately $1,620,000.
Alpha Cognition Price Performance
ACOG traded up $1.35 during trading on Monday, reaching $10.00. 352,389 shares of the company's stock were exchanged, compared to its average volume of 90,233. Alpha Cognition, Inc. has a 1 year low of $3.75 and a 1 year high of $10.79. The stock has a market capitalization of $160.20 million, a PE ratio of -3.91 and a beta of 2.48. The stock has a fifty day moving average of $5.44.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.38.
Analyst Ratings Changes
ACOG has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alpha Cognition in a research note on Friday. Raymond James upgraded shares of Alpha Cognition to a "moderate buy" rating in a research note on Tuesday, March 25th.
Check Out Our Latest Stock Report on Alpha Cognition
Alpha Cognition Profile
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Recommended Stories
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
